1.88 USD
-0.05 (-2.59%)
1.92 USD
+0.04 (+2.13%)
ChartMill assigns a Buy % Consensus number of 80% to JNCE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.65. This target is -12.29% below the current price.
JNCE was analyzed by 13 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about JNCE.
In the previous month the buy percentage consensus was at a similar level.
JNCE was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-02-24 | SMBC Nikko | Downgrade | Outperform -> Neutral |
| 2023-02-23 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2023-01-03 | Piper Sandler | Maintains | Overweight |
| 2022-11-11 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2022-08-31 | Raymond James | Maintains | Strong Buy |
| 2022-08-05 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2022-05-11 | Baird | Downgrade | Outperform -> Neutral |
| 2022-05-06 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2022-02-04 | Cowen & Co. | Upgrade | Market Perform -> Outperform |
| 2021-11-05 | Raymond James | Maintains | Outperform |
| 2021-09-14 | Raymond James | Upgrade | Market Perform -> Outperform |
| 2021-03-15 | Piper Sandler | Initiate | Overweight |
JOUNCE THERAPEUTICS INC / JNCE FAQ
What is the average price target for JOUNCE THERAPEUTICS INC (JNCE) stock?
13 analysts have analysed JNCE and the average price target is 1.65 USD. This implies a price decrease of -12.29% is expected in the next year compared to the current price of 1.88.
What is the consensus rating for JNCE stock?
The consensus rating for JOUNCE THERAPEUTICS INC (JNCE) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for JOUNCE THERAPEUTICS INC stock?
The number of analysts covering JOUNCE THERAPEUTICS INC (JNCE) is 13.